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Objectives:  
To develop a safe and effective protocol for the clinical control of Type 1 diabetes 
using conventional self-monitoring blood glucose (SMBG) measurements, and 
multiple daily injection (MDI) with insulin analogues.  To develop an in silico 
simulation tool of Type 1 diabetes to predict long-term glycaemic control outcomes of 
clinical interventions. 
 
Methods:  
The virtual patient method is used to develop a simulation tool for Type 1 diabetes 
using data from a Type 1 diabetes patient cohort (n=40).  The tool is used to test the 
adaptive protocol (AC) and a conventional intensive insulin therapy (CC) against 
results from a representative control cohort.  Optimal and suboptimal basal insulin 
replacement are evaluated as a function of self-monitoring blood glucose (SMBG) 
frequency in conjunction with the (AC and CC) prandial control protocols. 
 
Results:  
In long-term glycaemic control, the AC protocol significantly decreases HbA1c in 
conditions of suboptimal basal insulin replacement for SMBG frequencies ≥6/day, 
and reduced the occurrence of mild and severe hypoglycaemia by 86-100% over 
controls over all SMBG frequencies in conditions of optimal basal insulin. 
 
Conclusions:  
A simulation tool to predict long-term glycaemic control outcomes from clinical 
interventions is developed to test a novel, adaptive control protocol for Type 1 
diabetes.  The protocol is effective and safe compared to conventional intensive 
insulin therapy and controls.  As fear of hypoglycaemia is a large psychological 
barrier to glycaemic control, the AC protocol may represent the next evolution of 
intensive insulin therapy to deliver increased glycaemic control with increased safety. 
Further clinical or experimental validation is needed to fully prove the concept. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. INTRODUCTION 
 
Control of Type 1 diabetes is a widely studied and experimented research field.  
Previously published control methods are diverse, using different routes of insulin 
administration and glucose measurement.  Since the 1970s, the closed loop artificial 
endocrine pancreas (AEP) has been heralded as the solution (as reviewed in [1]).  
While no commercial product currently exists, the systems in current clinical use that 
are likely to constitute the components of an extracorporeal artificial pancreas are the 
continuous subcutaneous insulin infusion (CSII) pump and a continuous glucose 
measurement (CGM) device.  Advanced control algorithms and methods to ‘close the 
loop’ have also been widely studied (as reviewed in [2-4]) in spite of early and 
ongoing limitations in sensors and pumps.  Currently, the use of open-loop CGM 
and/or CSII has resulted in at best, a modest clinical advantage over conventional 
methods of insulin administration or multiple daily injection (MDI) (as reviewed in 
[5, 6]).  Additionally, these systems are only used by a small population of Type 1 
diabetics due to high upfront costs, costs of consumables, complexity, and the 
extensive healthcare infrastructure and support required.  Prevalence of CSII use is as 
low as 2% of the Type 1 diabetes population in the UK and up to 15-20% elsewhere 
and the US [7].   
 
Hence, there is a more practical and urgent need to address the large majority of the 
Type 1 diabetes population using conventional glucose measurement i.e. self-
monitoring blood glucose (SMBG) and insulin administration i.e. MDI methods, and 
for whom current conventional or intensive therapies are failing to deliver 
recommended levels of glycaemic control [8].  In the US, over 50% of diagnosed 
diabetics aged 20-64 are deemed ‘out of control’ [9].  The higher accuracy of bedside 
capillary blood glucose meters [10, 11], and the latest insulin analogues for MDI 
therapy [12], coupled with better control methods have the potential to provide better 
care to the majority of outpatient or ambulatory Type 1 diabetics than currently 
observed.  Such techniques must necessarily be simple to implement to ensure broad 
clinical uptake by the diabetes population. 
 
Previously, a system model of the Type 1 insulin-glucose regulatory system and its 
identification on a virtual patient cohort has been performed.  This study reports the 
development of a simple and practical adaptive method for control of Type 1 diabetes, 
and subsequent in silico simulation on a virtual patient cohort using the system model 
developed previously.  
 
3.1 Glucose measurement, insulin type and meals 
 
The control protocols developed and tested in this study aim to treat the broad Type 1 
diabetes population using conventional techniques e.g. SMBG and MDI therapy.  
Hence, the control protocols may only receive discrete glucose data at sparse intervals 
characteristic of SMBG.  Measurement frequencies of 2, 4, 6 8 and 10/day are 
simulated in this study. 
 
The AIDA on-line2 virtual cohort is treated with a range of short-acting, older 
intermediate/long-acting, or biphasic insulin [13].  In this study, only rapid-acting MI 
analogues and the basal insulin analogue glargine are used.  Insulin analogues have a 
more physiological and less variable pharmacokinetic profile than traditional insulin 
preparations [14] and allow more faithful basal-bolus insulin replacement [15].  
Clinically, reduced hypoglycaemia and glycosylated haemoglobin (HbA1c) have been 
associated with insulin glargine and MI [16-18].  MI injected at the start of meals 
reduced postprandial glucose excursions compared to regular human insulin injected 
30mins prior [18].  In addition, only one daily insulin glargine injection is required for 
basal insulin replacement [19].  These are the key clinical reasons insulin analogues 
are chosen.  While suboptimal glycaemic control is as much a symptom of poorly-
adapted treatment strategy [20] as insulin type, it is logical to begin with the least 
compromised insulin preparations.  The insulin model used in this study is capable of 
modelling the pharmacokinetic profiles of both MI analogues and insulin glargine [21, 
22].   
 
The meal carbohydrate content is assumed known to the patient through carbohydrate 
counting [23-25].  While the technique is only approximate and can be prone to 
inaccuracy [26], it remains the key clinical strategy recommended to estimate the 
glycaemic effect of meals for the purpose of adjusting insulin dosage [8]. 
 
3.2 Control methodology 
 
In this study, two prandial insulin treatment protocols, a conventional control protocol 
(CC) and the adaptive control (AC) protocol developed in this study, are simulated in 
silico.  The controls protocol is an unpublished protocol used to treat the AIDA on-
line2 cohort and is not the AIDA2 insulin dosage advisor [27].  The controls group 
results are calculated from the AIDA on-line2 patient data (the same data used to 
generate the virtual patient profiles for this in silico study).  Hence, in silico 
simulation is not required for the controls group.   
 
The AIDA on-line2 data is a simulation of the patient steady-state response to fixed, 
daily insulin and dietary stimuli.  To make the results of this study comparable, 
simulations are performed over a period of three days with the same, fixed insulin and 
dietary stimuli.  Plasma glucose, insulin, and meal Ra profiles from the third day are 
considered steady-state (AIDA assumes the data from the second day are steady state 
[27]) and are taken as the final result.   
 
For each tested protocol, SMBG frequencies of 2, 4, 6, 8 and 10/day are tested.  In 
addition, a basal insulin titration regimen is used with both protocols to observe the 
outcome of optimal basal insulin replacement using insulin glargine compared to 
controls.  The target blood glucose is 5mmol/l and a maximum bolus dose of 15U is 
assumed for both protocols. 
 
3.2.1 Conventional control (CC) 
 
The CC protocol is based on a published IIT [28-30].  The protocol administers a 
bolus at the start of the meal, tmeal,i (where tmeal,i is the time of the ith meal).  One 
glucose measurement at the start of the meal imealG  is required to calculate the bolus 
size.  The CC protocol is not adaptive as it uses fixed, suboptimal patient-specific 
parameters determined from the original AIDA on-line2 patient data.  Referring to 
Figure (1), the Carbohydrate-to-Insulin (CIR) ratio is determined for each patient 
using the 450 Rule (37 out of the 40 patients in the cohort are treated with regular 
insulin) [29].  The CIR can also be calculated using Equation (1).  
 
  DoseInsulin Daily Total
450insulin]regular  per U carb of [g CIR =  Eq. 1 
 
(Figure (1) here) 
 
Referring to Figure (2), an insulin sensitivity factor (ISF) is similarly determined for 
each patient using the 1500 Rule for regular insulin [30].  The ISF can also be 
calculated using Equation (2). 
 
  DoseInsulin Daily Totalx  18
1500insulin]regular  per U [mmol/l ISF =  Eq. 2 
 
(Figure (2) here) 
 
Using the patient CIR and ISF parameters, the CC protocol then calculates the ith 
prandial insulin dose using Equation (3) assuming that the ith meal carbohydrate 
count is known from carbohydrate counting. 
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3.2.2 Adaptive control (AC) 
 
The AC protocol utilises an adaptive method to determine the prandial insulin dose.  
The protocol comprises a twin bolus regimen per meal, with a conservative initial 
bolus, and an aggressive second bolus to accurately restore glycaemia to basal.  The 
second bolus is administered 90mins after the start of the meal and hence, the first 
bolus.  The first bolus is dosed according to the CC protocol.  As such, two glucose 
measurements are required per meal, imealG 1,  and imealG 2, before each bolus, at tmeal,i and 
tmeal,i+90 (where tmeal,i is the time of the ith meal).   
 
This time interval between boluses of 90mins is not arbitrary.  In normal individuals, 
plasma glucose is restored to pre-meal basal levels in approximately 120mins [31] for 
a normal meal (~1g glucose/kg body weight) and up to 360mins [32] for a very large 
meal (~4.5g glucose/kg body weight).  The 90min time interval chosen ensures 
minimal postprandial hyperglycaemic exposure.  In addition, the time to peak plasma 
concentration after MI injection ranges from 30-70mins [33], which ensures the 
second bolus is administered only after the plasma insulin concentration from the first 
bolus has peaked, and approximately 30mins to the peak pharmacodynamic effect of 
the first bolus [34].  Hence, the 90min time interval is a compromise, injecting the 
second bolus as late as needed for the first bolus to reach its pharmacodynamic peak 
for safety, while ensuring that the plasma insulin concentration does not wane, but is 
maintained and increased as necessary with the second bolus as a correction to 
minimise the postprandial glycaemic excursion. 
 
Referring to Equation (4), the AC protocol is adaptive by optimising the patient-
specific model parameter SI to glucose measurement data.  Accurately identifying the 
current patient condition in SI allows the safer administration of the aggressive insulin 
bolus.  Referring to Equation (5), G(t) for the identification of SI is linearly 
interpolated from the glucose measurements imealG 1,  and imealG 2, .  For the ith meal, the 
identified patient iIS ,  between the measurements at tmeal,i and tmeal,i+90 is used to 
predict the glycaemic response of the patient in the period ≥ tmeal,i+90 to some 
prediction end point, tpred (refer Equation (6)). 
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Substituting the measurements, imealG 1,  and imealG 2,     
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Then, assuming IS is constant over the prediction horizon, 
( ) iIpredimealpredI StttS ,,, 90 =≤≤+       Eq. 6 
 
Once the patient iIS , is known, the second bolus dose is determined iteratively.  From 
Equation (6), a predicted glycaemic response is generated using iIpredI SS ,, = up to a 
prediction horizon of 2hrs (tpred = tmeal,i+90 + 120).  The objective of the iteration is to 
achieve the 5mmol/l target blood glucose level from the predicted glycaemic response 
within the 2hr prediction horizon.  If imealG 2, ≤ target blood glucose level of 5mmol/l or 
if the iteration results in a zero dose (the predicted glucose response without an 
administered second bolus achieves the target blood glucose level within the 
prediction horizon) then no second bolus is administered.  If the iteration results in a 
dose exceeding the 15U maximum bolus dose, then the full 15U is administered.  In 
all iterations, using the models means all incoming glucose and insulin from prior MI 
and insulin glargine doses can be accurately accounted for in determining the 
correction bolus. 
 
3.3 Basal insulin titration regimen 
 
To optimise basal insulin replacement, a protocol based on the forced-titration 
regimens of Fritsche et al. [35] and Riddle et al. [36] is used (see Table (1)).  Unlike 
other basal dosing schemes [37, 38], this regimen has been shown to be clinically 
effective in a treat-to-target trial [36].  The Fritsche et al. protocol does not specify a 
dose decrement if hypoglycaemia occurs, but the similar Riddle et al. protocol 
specifies a small dose decrement of 2-4U/day if the fasting plasma glucose (FPG) is 
below 3.0mmol/l.  Hence, referring to Table (1), the protocol decreases the basal dose 
by 2U/day if FPG<3mmol/l and by 4U/day if FPG<2mmol/l.   
 
(Table (1) here) 
 
As in Riddle et al. [36], the FPG is assumed to be the pre-breakfast blood glucose 
level and is closest to the ADA definition of FPG of ‘no caloric intake for at least 
8hrs’ [8].  The single daily glargine dose is injected at the last meal of the day instead 
of bedtime (as in Riddle et al.) as it does not require assumptions about bed times and 
is unlikely to affect the titration scheme.  Unlike Riddle et al., the initial basal dose is 
chosen to be 80% of the total basal dose from the original patient data, which is 
recommended for patients changing over to insulin glargine from other basal insulin 
types [39].  The Riddle et al. initial basal dose of 10U is recommended only for 
insulin naïve patients and is less suitable for this study [39].  The maximum insulin 
glargine dose is limited to 80U (hence 80U/day) even though doses up to 100U can be 
clinically prescribed [39].  In the case of suboptimal basal insulin replacement, the 
basal insulin therapy from the controls cohort (the AIDA on-line2 patient data) is used.   
 
3.4 Location of SMBG measurements 
 
SMBG frequencies of 2, 4, 6, 8 and 10/day are examined.  For both the CC and AC 
protocols, the first SMBG measurement is always located at the start of breakfast (the 
approximate FPG) to titrate the basal insulin dose according to the Fritsche et al. 
protocol (see Section 3.5).  For the CC protocol, each subsequent SMBG 
measurement is located at the start of the meal in descending order of meal size.  As 
the AC protocol requires 2 SMBG measurements per meal, the second SMBG 
measurement is always 90mins after breakfast.  Each subsequent pair of SMBG 
measurements is located at the start and 90mins after the start of the meal in 
descending order of meal size.  Thus, additional pairs of measurements occur at 
lunch/dinner followed by between-meal snacks.  Hence, for an equivalent SMBG 
frequency, the CC protocol covers double the number of meals.   
 
 
 
3.5 HbA1c calculation 
 
Glycosylated haemoglobin, HbA1c is one of two clinical assessment techniques for 
glycaemic control recommended by the ADA [8].  The test assesses glycaemic control 
over the preceding 2-3 months [40].  Like AIDA [27], the control simulations in this 
study are for steady-state glucose and insulin stimuli.  The resulting steady-state 
glycaemic response can then be used to calculate an indicative and approximate 
HbA1c value [41], if the control is assumed to be relatively constant over a 2-3 month 
period.  From Rohlfing et al. [41], HbA1c can be defined as a linear function of mean 
plasma glucose only.  Referring to Figure (3) of data reproduced from Rohlfing et al., 
an HbA1c regression equation can be estimated. 
 
(Figure (3) here) 
 
2.25MBG5.0HbA1c +=        Eq. 7 
where 
[mmol/l] ionconcentrat glucose blood mean MBG =  
 
The MBG is calculated as the arithmetic mean of the 24h simulated glycaemic profile 
(1min time step).  Compared to the HbA1c regression equation in Equation (8) adapted 
from by AIDA on-line2 [42], the Rohlfing et al. equation is more conservative.   
 
2.87MBG6.0HbA1c +=        Eq. 8 
 
The HbA1c value calculated with Equation (7), while approximate and only if the 
control is assumed to persist for 2-3 months, provides a clinical significant 
performance metric to the results of this study.  In particular, the DCCT [43] and 
others have shown clinical outcomes as functions of HbA1c, which is a reliable and 
accepted metric in large intervention trials. 
 
3.6 Summary of simulations performed 
 
4 controllers are simulated.  These controllers are: 
 
• AC prandial insulin protocol - optimal basal insulin 
• AC prandial insulin protocol - suboptimal basal insulin 
• CC prandial insulin protocol - optimal basal insulin 
• CC prandial insulin protocol - suboptimal basal insulin  
 
For each controller, SMBG frequencies of 2, 4, 6, 8 and 10/day are simulated, giving 
20 simulations in total (5 SMBG frequencies simulated per controller type).  In 
addition: 
 
• The controls cohort results are calculated from the AIDA on-line2 patient data 
(the same data used to generate the virtual patient profiles for this in silico 
study) and is not the AIDA2 insulin dosage advisor [27].  No in silico 
simulation is performed for the controls group. 
• Optimal basal insulin replacement is performed using the Fritsche-Riddle 
basal insulin forced-titration regimen.  For suboptimal basal insulin 
replacement, the basal insulin therapy from the controls cohort (the AIDA on-
line2 patient data) is used.   
 
HbA1c distributions are compared using a non-parametric, two-tailed Wilcoxon 
signed-rank test.  An asymptotic significance value of <0.05 is considered statistically 
significant.  All calculations and analyses were performed using SPSS® (SPSS Inc., 
Chicago, IL, USA). 
 
2. RESULTS AND DISCUSSION 
 
The results of the in silico control simulation are as follows.  A sample simulation is 
shown in Figure (4) of Patient 6 under control by the AC protocol with a SMBG 
frequency of 6/day.  From this result, a patient specific HbA1c can be calculated for 
this patient and control scheme. 
 
(Figure (4) here) 
 
4.1 HbA1c 
 
Figures (5-8) show the empirical cumulative distribution function (CDF) of HbA1c for 
the AC and CC protocols with the controls group for comparison, with and without 
optimal basal insulin replacement.   
 
(Figure (5-6) here) 
 
Referring to Figure (5) and Table (2), only 52.5% of the controls group cohort have 
an HbA1c<7.0% while 40% had <6.5%.  These thresholds are noteworthy as they are 
the HbA1c glycaemic goals recommended by the ADA [8] and AACE [44] 
respectively.  Only 22.5% had an HbA1c<6% which is the normal HbA1c level.  The 
percentage of the controls cohort that meet the ADA recommended glycaemic goal of 
HbA1c ≤7.0% is in agreement with the figure of 48.9% of the US adult diabetes 
population being ‘in control’ [9], which supports the controls group as a realistic 
representation of the broad diabetes population and its treatment. 
 
(Table (2) here) 
 
4.1.1 Suboptimal basal insulin 
 
Compared to controls, both protocols with suboptimal basal insulin replacement 
perform significantly better for SMBG frequencies ≥4/day and ≥6/day for the CC and 
AC protocols respectively.  By design, the CC protocol covers twice as many meals as 
the AC protocol and this advantage is apparent at lower SMBG frequencies.  At 
higher SMBG frequencies, the AC protocol is able to cover most meals in the day 
with increased accuracy, outperforming the CC protocol significantly for all SMBG 
frequencies ≥6/day.  At a SMBG frequency of 6/day, 90% and 72.5% of the cohort 
meet ADA and AACE clinical recommendations respectively compared to 75% and 
60% for the CC protocol. 
 
This result is in agreement with clinical results of long-term control using MI.  It has 
been shown that optimal basal insulin replacement to the use of MI is required to 
achieve maximum benefit [18, 33, 45].  The pharmacokinetic profile of MI enables 
truer bolus insulin replacement than regular human insulin and as such, requires a 
truer basal insulin regiment.  Basal insulin regiments developed and optimised to 
regular insulin boluses will be suboptimal with MI boluses.  This is evident for both 
AC and CC protocols with suboptimal basal insulin replacement, which have non-
significant HbA1c to controls for SMBG frequencies less than ~3/day. 
 
4.1.2 Optimal basal insulin 
 
With optimal basal insulin replacement, glycaemic control is further enhanced.  For a 
6/day SMBG frequency, the AC protocol now results in 100% of the cohort controlled 
to ADA guidelines, 92.5% to AACE guidelines, and 85% have normal HbA1c levels.  
However, the difference between CC and AC protocols with suboptimal basal insulin 
replacement (Figure (7)) is much larger than with optimal basal insulin treatment 
(Figure (8)).  As expected, the AC protocol exceeds the CC protocol for all SMBG 
frequencies except 2/day.  However, only the result from the 8/day SMBG frequency 
is statistically significant.  For AACE and the normal HbA1c thresholds given a 6/day 
SMBG frequency, the difference between the two protocols is just 2.5% of the cohort 
or 1 patient.   
 
(Figure (7-8) here) 
 
These results indicate that if basal insulin replacement is optimal, both prandial 
insulin protocols perform adequately.  However, if basal insulin replacement is 
suboptimal and insulin requirements in the post-absorptive period are not met, then 
the AC protocol compensates, especially at SMBG frequencies ≥6/day where 
sufficient measurements exist to cover most of the meals in the day.  The HbA1c 
results are summarised in Figure (9). 
 
(Figure (9) here) 
 
4.2 Hypoglycaemia 
 
The hypoglycaemic level of 3.9mmol/l defined by the ADA is adopted in this study 
[46] as the mild hypoglycaemic threshold.  The glucose level to define severe 
hypoglycaemia is assumed to be 3mmol/l.  Cognitive function is impaired from 
~3mmol/l [47, 48], which matches the definition of the ADA for severe 
hypoglycaemia as ‘an event requiring assistance of another person to actively 
administer [resuscitative actions]’ [46].  While these definitions are used globally in 
this study, it is acknowledged that the hypoglycaemic level and response is complex 
and patient-specific [49]. 
 
4.2.1 CC protocol 
 
Referring to Figures (10-13), the total time spent by the cohort in mild (thypo,mild) and 
severe hypoglycaemia (thypo,sev) is shown as a percentage.  For the controls group, 
thypo,mild is 7.7%.  From Figure (10) for the CC protocol with suboptimal basal insulin 
replacement, thypo,mild is relatively constant over all SMBG frequencies at 4.2-4.9%.  
For the CC protocol with optimal basal insulin replacement, thypo,mild decreases with 
increasing SMBG frequency with the highest thypo,mild of 8.5% occurring for a SMBG 
frequency of 2/day.  This figure exceeds the controls group (7.7%) and the suboptimal 
basal insulin CC protocol (4.3%).  At a SMBG frequency of 4/day, thypo,mild is 6.5% 
compared to 4.5% for the suboptimal basal insulin CC protocol.  At a SMBG 
frequency of 6/day, thypo,mild is comparable to the suboptimal basal insulin CC protocol 
(4.5% compared to 4.2%), dropping further to 2.9% compared to 4.9% for the 
suboptimal basal insulin CC protocol at a SMBG frequency of 10/day. 
 
(Figure (10) here) 
 
Similarly, thypo,sev is relatively constant at ~1.8% for the CC protocol with suboptimal 
basal insulin replacement.  Like thypo,mild, thypo,sev under the CC protocol with optimal 
basal insulin replacement is maximum at 1.2% for a SMBG frequency of 2/day and 
decreases to 0.6% for a SMBG frequency of 10/day.  For the controls group, thypo,sev is 
3.5%.   
 
In summary, across all SMBG frequencies, thypo,sev under the optimal basal insulin CC 
protocol is reduced by 66-83% over controls and by 33-67% over the suboptimal 
basal insulin CC protocol.  However, thypo,mild is increased at least until a SMBG 
frequency of 4/day and is decreased for all SMBG frequencies >6/day.  Under the CC 
protocol and with a low SMBG frequency e.g. 2-4/day, the prandial glycaemic 
excursion especially for the last meal of the day is usually not completely restored to 
basal.   
 
This failure to reach a basal level overnight is important because it affects the pre-
breakfast glucose measurement used for the titration of the basal insulin dose, 
resulting in an aggressive dose increase and increased mild hypoglycaemia.  
Fortunately, this problem does not result in increased severe hypoglycaemia and in 
fact, optimal basal insulin replacement with insulin glargine results in lower 
occurrences of severe hypoglycaemia across all SMBG frequencies.  With SMBG 
frequencies of 6/day or more, occurrences of both mild and severe hypoglycaemia are 
reduced over controls and the suboptimal basal insulin CC protocol. 
 
4.2.2 AC protocol 
 
Referring to Figure (11) for the AC protocol with suboptimal basal insulin 
replacement, thypo,mild is relatively constant over all SMBG frequencies at 4.2-4.4%.  
For the AC protocol with optimal basal insulin replacement, thypo,mild decreases with 
increasing SMBG frequency with the highest thypo,mild of 3.1% and 3.2% occurring for 
SMBG frequencies of 2/day and 4/day respectively.  This figure is 60% less than the 
controls group (7.7%) and 28% less than the suboptimal basal insulin CC protocol 
(4.4%).  At a SMBG frequency of 8/day, thypo,mild reaches a nadir of 0.7% before 
increasing to 1.3% for a SMBG frequency of 10/day.   
 
(Figure (11) here) 
 
Similarly, thypo,sev is relatively constant at ~1.8% for the AC protocol with suboptimal 
basal insulin replacement.  Like thypo,mild, thypo,sev under the AC protocol with optimal 
basal insulin replacement is maximum at 0.6% for SMBG frequencies of 2/day and 
4/day but decreases to zero percent for SMBG frequencies ≥6/day.   
 
In summary, across all SMBG frequencies, thypo,sev under the AC protocol with 
optimal basal insulin replacement is reduced by 86-100% over controls and by 72-
100% over the AC protocol with suboptimal basal insulin replacement.  Across all 
SMBG frequencies, thypo,mild under the AC protocol with optimal basal insulin 
replacement is reduced by 58-91% over controls and 27-84% over the AC protocol 
with suboptimal basal insulin replacement.  Prandial glycaemic excursions are more 
completely restored to basal under the AC protocol even with a low SMBG 
frequency.  This results in a more accurate pre-breakfast glucose measurement for 
basal insulin titration on the forced-titration regimen with lower resultant mild and 
severe hypoglycaemia. 
 
4.2.3 Summary of hypoglycaemia results 
 
Referring to Figure (12) for optimal basal insulin replacement, the AC protocol 
outperforms the CC protocol in hypoglycaemia occurrence over all SMBG 
frequencies.  Given suboptimal basal insulin replacement, occurrence of 
hypoglycaemia both mild and severe is similar between the two protocols (see Figure 
(13)).  The results of this comparison are similar to that of HbA1c whereby the 
advantage of the AC protocol is most apparent in conditions of poor basal insulin 
replacement.   
 
Contrary to the DCCT [43], hypoglycaemia did not increase under the conventional 
IIT (CC protocol) in this study.  In both cases of suboptimal and optimal basal insulin 
replacement, severe hypoglycaemia is reduced for all SMBG frequencies compared to 
controls.  This result is in excellent agreement with the study by Sämann et al. [20] 
where implementation of a flexible IIT protocol improved glycaemic control without 
increased risk of severe hypoglycaemia.  The protocol in the Sämann et al. study 
consists of a structured inpatient training course, implemented into routine care with 
continuous quality assurance on a national level.  Hence, it is reasonable to assume 
high patient protocol adherence and that the conditions in this study are similar to that 
inherent of the in silico simulation, which assumes full patient adherence. 
 
(Figure (12-13) here) 
 
4.3 SMBG frequency 
 
The frequency of SMBG has been known to affect glycaemic control, as reviewed in 
[50].  For Type 1 diabetes, the ADA [8] and AACE [44] both recommend a SMBG 
frequency ≥3/day and in a study by Monnier et al. [51], 5- to 8-point daily glucose 
monitoring is recommended.  Davidson et al. [52] has modelled HbA1c and SMBG 
with Equation (9). 
 
( )39.1dayper  tests
32.599.5HbA1c
+
+=      Eq. 9 
 
Referring to Figure (14), the data from Davidson et al. is reproduced with the median 
cohort HbA1c of this study for the various protocols and basal insulin replacement 
regimens.   
 
The Davidson et al. curve follows closely the suboptimal basal insulin CC protocol.  
This result supports the validity of the in silico simulation, which produces a similar 
HbA1c simulating a conventional IIT under suboptimal basal insulin replacement.  
With SMBG frequency >4/day, the suboptimal basal insulin AC protocol reduces the 
median HbA1c over the CC protocol under the same basal insulin replacement.  Both 
protocols with optimal basal insulin replacement result in a normal median HbA1c 
even at a low SMBG frequency of 2/day although the AC protocol results in 
marginally lower HbA1c for all SMBG frequencies ≥6/day.  This result also implies 
that clinically, poor glycaemic control is mainly a result of suboptimal basal insulin 
replacement.  As shown in Section 4.1.2 basal insulin replacement has the single, 
most significant effect on HbA1c, much more so than the difference between AC and 
CC prandial insulin protocols.   
 
(Figure (14) here) 
 
The forced-titration regimen of basal insulin dosing has been found to be safe only if 
sufficient SMBG and consequently, prandial control is applied in order for the 
assumed FPG value to be an accurate.  The basal insulin forced-titration regimen 
relies on a single, pre-breakfast FPG value and if a patient is poorly controlled 
prandially, the assumed FPG value is likely to be influenced by the postprandial 
excursion from the previous night.  From this study, this minimum SMBG frequency 
is approximately ~6/day for a conventional IIT (CC protocol).  With the AC protocol, 
the SMBG frequency does not present a safety issue regardless of basal insulin 
replacement. 
 
Referring to Table (2), the suboptimal basal insulin CC protocol (a conventional IIT) 
and a SMBG frequency of 4/day results in 60% of the cohort controlled to ADA 
guidelines, and 25% to normal HbA1c levels.  With 6- or 8-point daily glucose 
monitoring, these figures are 75.0% and 32.5% respectively.  Hence, control with the 
minimum ADA recommended SMBG frequency, or even the Monnier et al. daily 8-
point measurements is unsatisfactory if the protocol implemented is a conventional 
IIT with suboptimal basal insulin replacement.  From this study, glycaemic control 
with the suboptimal basal insulin CC protocol saturates at a SMBG frequency of 
6/day with 75% of the cohort meeting ADA guidelines.  Hence, a SMBG frequency of 
6/day should be the minimum for a conventional IIT with a suboptimal basal insulin 
regimen. 
 
With optimal basal insulin replacement, the adaptive AC protocol with a SMBG 
frequency of 4/day results in 97.5% of the cohort controlled to ADA guidelines, and 
82.5% to normal HbA1c levels.  In addition, mild hypoglycaemia is reduced by 27% 
and severe hypoglycaemia by 50% in comparison to the suboptimal basal insulin CC 
protocol.  With optimal basal insulin replacement, the CC protocol produces similarly 
excellent glycaemic control but mild hypoglycaemia is increased 103% compared to 
the AC protocol.  Fear of hypoglycaemia is frequently cited for deliberate insulin 
under-dosing, both prandial and basal [35, 53].  Hence, the adaptability of the AC 
protocol may represent the next evolution of IIT to deliver increased glycaemic 
control with increased safety. 
 
3. CONCLUSIONS 
 
An in silico simulation tool is presented that utilises an extended model of glucose 
kinetics, and the novel application of a subcutaneous insulin pharmacokinetic model.  
The virtual patient cohort and its default control protocol (the data of which is used 
for in silico simulation) can be considered a good representation of the broad diabetes 
population.  The simulation tool is used to develop a robust, adaptive protocol for 
prandial insulin dosing.   
 
In virtual trial simulations, the adaptive protocol has been shown to significantly 
decrease HbA1c in conditions of suboptimal basal insulin replacement for SMBG 
frequencies ≥6/day and reduce the occurrence of mild and severe hypoglycaemia by 
86-100% over controls over all SMBG frequencies in conditions of optimal basal 
insulin.  When a conventional IIT is employed in conditions of suboptimal basal 
insulin, the increase in cohort compliance to clinical control guidelines saturates at a 
SMBG frequency of 6/day.  In addition, under conventional IIT, the basal insulin 
forced-titration regimen requires a minimum SMBG frequency of 6/day to safely 
titrate the basal dose without increased hypoglycaemia.  The overaggressive basal 
dose titration with a conventional IIT at lower SMBG frequencies is likely to be 
caused by uncorrected postprandial hyperglycaemia from the previous night, resulting 
in an erroneous assumed FPG used for dose titration.   
 
With a SMBG frequency of 4/day and optimal basal insulin replacement, 97.5% of 
the cohort can be controlled to ADA clinical guidelines using the adaptive protocol, a 
result similar to a conventional IIT but which has 103% more mild hypoglycaemia.  
As fear of hypoglycaemia is a large psychological barrier to glycaemic control, the 
AC protocol may represent the next evolution of IIT that can deliver increased 
glycaemic control with increased safety.  Further clinical or experimental validation is 
needed to fully prove the concept. 
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FIGURES 
 
 
 
Figure 1 : The carbohydrate-to-insulin (CIR) ratio is determined for each patient using the 450 
Rule for regular insulin (37 out of the 40 patients in the cohort are treated with regular insulin 
with the rest on biphasic insulin).  Data reproduced from [29] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 : The insulin sensitivity factor (ISF) is determined for each patient using the 1500 Rule 
for regular insulin.  Data reproduced from [30] 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Estimating HbA1c from mean plasma glucose with linear regression.  Data reproduced 
from Rohlfing et al. [41] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: A sample in silico simulation of Patient 6 under control by the AC protocol with a 
SMBG frequency of 6/day 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Empirical cumulative distribution function (CDF) of HbA1c for the CC protocol with 
optimal and suboptimal basal insulin replacement compared to the controls group.  The ADA 
recommended glycaemic control level as measured by HbA1c ≤7% is shown with the percentage 
time spent above the threshold shown for each case.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 6: Empirical cumulative distribution function (CDF) of HbA1c for the AC protocol with 
optimal and suboptimal basal insulin replacement compared to the controls group.  The ADA 
recommended glycaemic control level as measured by HbA1c ≤7% is shown with the percentage 
time spent above the threshold shown for each case.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Empirical cumulative distribution function (CDF) of HbA1c for both AC and CC 
protocols with suboptimal basal insulin replacement compared to the controls group.  The ADA 
recommended glycaemic control level as measured by HbA1c ≤7% is shown with the percentage 
time spent above the threshold shown for each case.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Empirical cumulative distribution function (CDF) of HbA1c for both AC and CC 
protocols with optimal basal insulin replacement compared to the controls group.  The ADA 
recommended glycaemic control level as measured by HbA1c ≤7% is shown with the percentage 
time spent above the threshold shown for each case.  
 
 
 
 
 
 
 
 
 
 
  
Figure 9: The cohort percentage controlled to clinically relevant HbA1c levels (as recommended 
by the ADA [8] and AACE [44]) as compared to the controls group.  The normal HbA1c level of 
6.0% is shown for comparison 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Total time spent by the cohort, and the cohort median and 90% confidence band for 
the time spent in mild and severe hypoglycaemia under the CC protocol in conditions of optimal 
and suboptimal basal insulin replacement  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Total time spent by the cohort, and the cohort median and 90% confidence band for 
the time spent in, mild and severe hypoglycaemia under the AC protocol in conditions of optimal 
and suboptimal basal insulin replacement 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Total time spent by the cohort, and the cohort median and 90% confidence band for 
the time spent in mild and severe hypoglycaemia under AC and CC protocols and suboptimal 
basal insulin replacement 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 13: Total time spent by the cohort, and the cohort median and 90% confidence band for 
the time spent in mild and severe hypoglycaemia under AC and CC protocols and optimal basal 
insulin replacement 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Predicted HbA1c data from Davidson et al. [52] and the median cohort HbA1c of this 
study vs. SMBG frequency.  The Davidson et al. curve follows approximately the suboptimal 
basal insulin CC protocol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLES 
 
Table 1: The basal insulin dosing regimen used to optimise the single, daily insulin glargine dose 
based on the forced-titration regimens of Fritsche et al. [35] and Riddle et al. [36].  This regimen 
incorporates a dose decrement if hypoglycaemia occurs which the Riddle et al. protocol does not 
specify explicitly.  Unlike Riddle et al., the initial basal dose is chosen to be 80% of the total basal 
dose from the AIDA2 on-line cohort data, which is recommended for patients changing over to 
insulin glargine from other basal insulin types [39] 
 
 
Initial dose equivalent to 80% of total basal dose 
 
Fasting plasma 
glucose (FPG) 
[mmol/l] Increment in glargine dose 
(U/day) 
Decrement in glargine dose 
(U/day) 
≥10.0 8  
≥7.8 and <10.0 6  
≥6.7 and <7.8 4  
≥5.6 and <6.7 2  
≥3.0 and <5.6   
≥2.0 and <3.0  2 
<2  4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Summary of the cohort percentage controlled to ADA [8] and AACE [44] glycaemic 
control recommendations, and to normal HbA1c levels.  The percentage of the controls group 
controlled to ADA recommended HbA1c (52.5%) is in excellent agreement with the figure of 
48.9% of the US adult diabetes population being ‘in control’ [9] 
 
HbA1c [%]  <6.0 <6.5 <7.0 
Basal 
protocol 
type 
Prandial 
protocol 
type 
SMBG 
frequency 
[/day] 
 
Controls 22.5 40.0 52.5 
2 22.5 25.0 37.5 
4 25.0 42.5 60.0 
6 32.5 60.0 75.0 
8 32.5 60.0 75.0 
CC 
10 32.5 60.0 75.0 
2 15.0 25.0 30.0 
4 22.5 35.0 60.0 
6 37.5 72.5 90.0 
8 42.5 77.5 95.0 
Controls 
(suboptimal) 
AC 
10 57.5 85.0 97.5 
2 70.0 90.0 95.0 
4 80.0 92.5 95.0 
6 82.5 90.0 100.0 
8 82.5 90.0 100.0 
CC 
10 82.5 90.0 100.0 
2 62.5 77.5 90.0 
4 82.5 95.0 97.5 
6 85.0 92.5 100.0 
8 85.0 95.0 100.0 
Forced-
titration 
regimen 
(optimal) 
AC 
10 77.5 92.5 100.0 
 
 
